Subtype
Genitourinary System Carcinoma
CI-CAN-00000925Explore in graph →
1,501 active trials44 approved drugs143 evidence items
- NCIt
- C164141
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000925Explore in graph →
Clinical trials
4,919 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (758)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01285102 | Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer | terminated | Phase 1 | 4 | Fox Chase Cancer CenterOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT03287050 | Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma | terminated | Phase 2 | 6 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT01018563 | An Open Label Extension Study of the Efficacy of MORAb-003 | terminated | Phase 2 | 3 | MorphotekINDUSTRY | 2 | Dec 8, 2021 | clinicaltrials |
| NCT02767921 | sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer | terminated | Phase 1 | 2 | University of Southern CaliforniaOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT03712930 | Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency | terminated | Phase 2 | 13 | BeiGeneINDUSTRY | 4 | Nov 17, 2021 | clinicaltrials |
| NCT03408652 | Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies(MOSCAR) | terminated | Phase 3 | 1 | Centre Leon BerardOTHER | 1 | Oct 22, 2021 | clinicaltrials |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | PfizerINDUSTRY | 4 | Oct 14, 2021 | clinicaltrials |
| NCT02565901 | Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 28 | University of WashingtonOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT03115801 | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers | terminated | Phase 2 | 6 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT02885649 | Enzalutamide Before Surgery in Treating Patients With Kidney Cancer | terminated | Early Phase 1 | 3 | Rutgers, The State University of New JerseyOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT02959554 | Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control(NIVOSWITCH) | terminated | Phase 2 | 49 | AIO-Studien-gGmbHOTHER | 2 | Sep 8, 2021 | clinicaltrials |
| NCT03608618 | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma | terminated | Phase 1 | 14 | MaxCyte, Inc.INDUSTRY | 1 | Sep 5, 2021 | clinicaltrials |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | terminated | Phase 1 | 2 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 31, 2021 | clinicaltrials |
| NCT04066595 | Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.(CabUC) | terminated | Phase 2 | 7 | Johannes Gutenberg University MainzOTHER | 1 | Aug 30, 2021 | clinicaltrials |
| NCT01649180 | NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma(PrE0801) | terminated | Phase 2 | 3 | PrECOG, LLC.OTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02985021 | Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies | terminated | Phase 2 | 2 | Seattle Institute for Biomedical and Clinical ResearchOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT03829930 | Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer | terminated | Phase 1 | 6 | George Washington UniversityOTHER | 1 | Aug 2, 2021 | clinicaltrials |
| NCT04579133 | Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy | terminated | Phase 2 | 140 | Latin American Cooperative Oncology GroupOTHER | 1 | Jun 16, 2021 | clinicaltrials |
| NCT01147536 | Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence | terminated | Phase 2 | 12 | Agenus Inc.INDUSTRY | 2 | Jun 3, 2021 | clinicaltrials |
| NCT02693717 | Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2021 | clinicaltrials |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT03029585 | Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer | terminated | Phase 2 | 10 | NanOlogy, LLCINDUSTRY | 1 | Apr 27, 2021 | clinicaltrials |
| NCT01253668 | Brivanib Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT02853097 | Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients | terminated | — | 7 | University of Southern CaliforniaOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT03042312 | Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy(RESIST-PC) | terminated | Phase 2 | 71 | EndocyteINDUSTRY | 1 | Mar 24, 2021 | clinicaltrials |
| NCT01334047 | Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients | terminated | Phase 1 / Phase 2 | 5 | Steinar AamdalOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT00324740 | Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer | terminated | Phase 1 / Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2021 | clinicaltrials |
| NCT03261336 | Oral Calcitriol With Ketoconazole in CRPC | terminated | Phase 2 | 1 | Donald Trump, MDOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT00285415 | A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation | terminated | Phase 2 | 46 | Carilion ClinicOTHER | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03741712 | A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC | terminated | Phase 1 / Phase 2 | 9 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03514836 | A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 5 | SOTIO a.s.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) | terminated | Phase 1 | 13 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 27, 2021 | clinicaltrials |
| NCT02495103 | Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Jan 26, 2021 | clinicaltrials |
| NCT02844582 | Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 2 | 2 | University of California, DavisOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT03327662 | Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer(CTC-STOP) | terminated | Phase 3 | 12 | Institute of Cancer Research, United KingdomOTHER | 1 | Jan 6, 2021 | clinicaltrials |
| NCT02853162 | Ablative tReatment of Inoperable REnal Cell Carcinoma Using STereotactic Body Radiotherapy (ARREST-study)(ARREST) | terminated | Phase 2 | 30 | UMC UtrechtOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT02947152 | HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma | terminated | Phase 1 | 9 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 8, 2020 | clinicaltrials |
| NCT02131376 | Investigating a Novel Modifiable Factor Affecting Renal Function After Partial Nephrectomy: Cortical Renorrhaphy | terminated | N/A | 26 | Indiana UniversityOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT01673386 | A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC(TAURUS) | terminated | Phase 2 | 58 | AVEO Pharmaceuticals, Inc.INDUSTRY | 7 | Oct 27, 2020 | clinicaltrials |
| NCT02595918 | Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery | terminated | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Oct 23, 2020 | clinicaltrials |
| NCT01806064 | Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 173 | Tracon Pharmaceuticals Inc.INDUSTRY | 4 | Oct 19, 2020 | clinicaltrials |
| NCT03570476 | Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer | terminated | Phase 2 | 2 | University of WashingtonOTHER | 1 | Sep 21, 2020 | clinicaltrials |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | terminated | Phase 1 | 16 | Seagen Inc.INDUSTRY | 1 | Sep 17, 2020 | clinicaltrials |
| NCT01939028 | Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery | terminated | N/A | 58 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 27, 2020 | clinicaltrials |
| NCT03719300 | Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC | terminated | Phase 2 | 32 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 1 | Aug 19, 2020 | clinicaltrials |
| NCT03167151 | Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)(PemBla) | terminated | Phase 1 / Phase 2 | 6 | University of OxfordOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | terminated | Phase 1 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 29, 2020 | clinicaltrials |
| NCT02168062 | Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer | terminated | Phase 2 | 57 | University of California, San FranciscoOTHER | 1 | Jul 23, 2020 | clinicaltrials |
| NCT02212730 | A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031) | terminated | Phase 1 | 10 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 16, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Dec 20, 2021source: clinicaltrials